Kornimate/medical-research-clean huggingface dataset:
improving ambulatory community access after paralysis

Conditions: Stroke; Partial Paralysis; Spinal Cord Injury; Tetraplegia; Quadriplegia

Summary: the purpose of this research study is to evaluate the effectiveness of functional electrical stimulation (fes) provided by an implanted pulse generator (ipg) in correcting hip, knee and ankle function to improve walking in people with partial paralysis.

in a surgical procedure electrodes are inserted into muscles of the lower extremities to correct hip, knee and ankle function. the electrode leads are connected to an implanted pulse generator located in the abdomen. after a typical post-operative period of two to five days, the recipient will be discharged home for two to six weeks of moderate activity. following a 6 week period of laboratory exercise and training, functional use of the neuroprosthesis will begin at home and in the community with follow-up evaluations at 1, 3, 6 and 12 months. laboratory assessments include walking speed and distance, physiologic cost, muscle strength, measure of spasticity, and gait analysis with and without stimulation. a number of self-reporting instruments are administered to capture individual's participation, quality of life and various aspects of perceived community ambulation.

Eligibility criteria:
inclusion criteria: * problems walking because of paralysis for more than 6 months * weak hip flexors and extensors or excessive tone * weak ankle dorsiflexors (muscles bringing the foot up) * weak plantar flexors (ankle muscles for push-off) * foot drop that is causing "dragging" or "catching" toes during walking * swinging the leg sideways or hiking the hip to clear affected leg during stepping * endurance to walk at least 10 ft with minimal assistance * hip extension range to neutral * hip flexion range greater or equal to 90 degrees * ankle range to neutral * sufficient upper extremity function to use a walking aid * muscles respond to electrical stimulation exclusion criteria: * cardiac arrythmias * demand pacemaker * pregnancy * parkinson's disease * traumatic brain injury * autoimmune deficiency * uncontrolled diabetes * significant edema of the affected limb * active pressure ulcers or open wounds * sepsis or an active infection * severe osteoporosis * uncontrolled seizures * moderate depression

Keywords: stroke partial paralysis gait correction functional electrical stimulation paraplegia tetraplegia spinal cord injury
international registry on cardioversion of atrial fibrillation (mk-6621-051)

Conditions: Atrial Fibrillation

Summary: this study will create a prospective registry of consecutive patients with atrial fibrillation (afib) considered for cardioversion treatment to document up-to-date practice of in-hospital treatment, with a focus on the characterization of type of afib, as well as on treatments applied (drugs, devices, interventions and their combinations), and associated complications within 60 days after enrollment.


Eligibility criteria:
inclusion criteria: * participant with documented atrial fibrillation (confirmed by electrocardiogram) in the hospital setting at the time of enrollment * planned cardioversion (of atrial fibrillation) exclusion criteria: * already enrolled in this or any other clinical trial * atrial flutter

Keywords: atrial fibrillation afib cardioversion normal sinus rhythm arrhythmia af
a study of the cardiac effects of alxn1840 in healthy adults

Conditions: Healthy

Summary: this study will evaluate the effect of a supratherapeutic dose of alxn1840 on the heart rate (hr)-corrected qt interval (qtc) in healthy adult participants. moxifloxacin will be used as the active control.

this is a randomized, 3-treatment, 3-period, 6-sequence, crossover, placebo- and active-controlled, double-blind for alxn1840, open-label for moxifloxacin, in healthy adult participants. participants will be domiciled in the clinic for 7 days during treatment period 1 and for 6 days during treatment period 2 and 3. a single oral dose of each treatment (alxn1840, matching alxn1840 placebo, or moxifloxacin) will be administered on day 1 of each period following an overnight fast of at least 10 hours. there will be a minimum 14-day washout between study intervention administrations for each treatment period. cardiodynamic, pharmacokinetic, and safety assessments will be performed at certain times during the study. an end-of-study visit will occur 14 days (±2 days) after the last dose.

Eligibility criteria:
inclusion criteria: 1. nonsmoker. 2. body weight at least 60 kilograms (kg) for males or 52 kg for females and body mass index ≥18.0 and ≤30.0 kg/meter squared. 3. willing and able to follow protocol-specified contraception requirements. 4. participant has no clinically significant history or presence of ecg findings. exclusion criteria: 1. history or presence of clinical and/or lab disorders. 2. lymphoma, leukemia, or any malignancy within the past 5 years, or breast cancer within the past 10 years. 3. participant has abnormal blood pressure, defined as a supine blood pressure \ 140/90 mm hg. 4. serum potassium, calcium, or magnesium levels outside the normal range. 5. serum copper and/or ceruloplasmin values below the lower limit of normal at screening. 6. female participant has hemoglobin \<10.8 grams/deciliter (g/dl) and male participant has hemoglobin \<12.5 g/dl. 7. clinically significant multiple or severe allergies. 8. alanine aminotransferase, aspartate aminotransferase, serum creatinine, or total bilirubin greater than upper limit of normal (with the exception of gilbert's syndrome).

Keywords: electrocardiogram cardiac repolarization alxn1840 optimized qt correction qt interval correction thorough qt qt correction by fridericia individual qt correction wilson disease
a multicenter study evaluating the effectiveness of endo.angel in improving the quality of colonoscopy

Conditions: Adenoma

Summary: colonoscopy is a key technique in the detection and diagnosis of lower gastrointestinal diseases. high quality endoscopy results in better disease outcomes. however, the operant level of different endoscopists is significantly different.this study aims to construct a real-time quality monitoring system based on computer vision, named endo.angel, which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.

this study aims to construct a real-time quality monitoring system based on computer vision, named endo.angel, which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.criteria for inclusion and exclusion are determined prior to endoscopic examination. candidates who meet all inclusion criteria as well as do not meet all exclusion criteria are bring into the study. participants randomized before the examination, they are divided into the exposed group assisted by endo.angel or the non-exposed group without endo.angel. followup are conducted after the examination.study will be finished when all followup is done,and the examination result collected from participants will send to an independent review data analysis group.

Eligibility criteria:
inclusion criteria: 1. men or women over the age of 18 years old; 2. ability to read, understand and sign informed consent; 3. the investigator believes that the subject understands the flow of the clinical study and is willing and able to complete all the research procedures and follow-up visits in conjunction with the research procedure. exclusion criteria: 1. colonoscopy patients with absolute contraindications; 2. patients with biopsy contraindications; 3. inflammatory bowel disease, colorectal cancer, history of colorectal surgery; 4. women during pregnancy or lactation; 5. patients with multiple polyposis syndrome; 6. patients with known or suspected intestinal obstruction or perforation 7. previously failed colonoscopy; 8. the investigator believes that the subject is not suitable for high-risk disease or other special conditions in clinical trials.
the relationship between bone pelvis measurements and erectile function in patients who had nerve-sparing robot-assisted radical prostatectomy operation

Conditions: Erectile Dysfunction

Summary: in order to evaluate the relationship between bone pelvis measurements and erectile function in patients who underwent nerve-sparing robot-assisted radical prostatectomy, bone pelvis measurements will be measured from mri images of the patients before the operation and their erection quality will be evaluated with the iief-5 form. the erection quality of the same patients will be evaluated with the iief-5 form in the 3rd and 6th months after the operation. and it will be evaluated whether there is a relationship between the erection quality of the patients before and after the operation and their bone pelvis measurements.


Eligibility criteria:
inclusion criteria: * having bilateral nerve-sparing robot-assisted radical prostatectomy operation * having a regular sexual life exclusion criteria: * having received neoadjuvant therapy * having a history of radiotherapy to the pelvic area * the need to receive postoperative hormono-radiotherapy
impact of metformin in teens with polycystic ovary syndrome (pcos) on oral contraceptive therapy

Conditions: Polycystic Ovary Syndrome

Summary: oral contraceptives are known to improve menstrual cycles and symptoms in pcos, however may increase cholesterol. metformin, a drug to improve insulin resistance, may benefit metabolic state. this study is to determine whether metformin added to oral contraceptive therapy in adolescent women with pcos improves metabolic state.the study will also test a lifestyle improvement program to reduce weight.

polycystic ovary syndrome (pcos) is a heterogeneous condition characterized by chronic anovulation and androgen excess that occurs in 4-8% of unselected adult women. although signs and symptoms of the disorder typically appear at the time of puberty, diagnosis is often delayed until adulthood. at least 50% of adult women with pcos are obese, resulting in a more severe clinical picture. obesity among adolescents has been increasing in recent years, with overrepresentation of females who show evidence of hyperandrogenism and irregular periods, suggesting an association of obesity and pcos at an early age. recent data, however, have drawn attention to the long-term risks of pcos, including diabetes and cardiovascular disease. insulin resistance plays a critical role in the pathophysiology of pcos and is thought to be the metabolic abnormality most closely linked to an increased risk of diabetes and heart disease. traditional treatments with oral contraceptives are associated with reduction in serum androgens and improvements in menstrual cycles in adolescents with pcos, however these have not been well-studied in obese adolescents. oral contraceptives may worsen the dyslipidemia seen in obese women with pcos and do not address the insulin resistance. metformin, an insulin sensitizing agent, has been shown to improve metabolic features of pcos, but combination therapy with oral contraceptives has never been studied in the obese adolescent with pcos. the major hypothesis of this proposal is that metformin will improve the metabolic profile of obese adolescent girls with pcos treated with oral contraceptives. additionally, a secondary hypothesis will be that compliance with a concurrent lifestyle modification program with be associated with the most significant improvements.

Eligibility criteria:
inclusion criteria:age 12-18 years; menstrual irregularity; overweight; must be able to swallow capsules; at lease 6 months since onset of first menstrual cycle. exclusion criteria:diabetes; kidney or liver disease; tobacco use; depression or bipolar disease; contraindication to exercise; weight \> 300 lbs.

Keywords: polycystic ovary syndrome overweight adolescent girls irregular menstrual cycles
hand function for tetraplegia

Conditions: Spinal Cord Injury; Tetraplegia

Summary: the purpose of this study is to evaluate the effectiveness of an implanted stimulator for providing hand function to individuals with cervical level spinal cord injury. the device stimulates the paralyzed muscles of the hand and forearm. the user of the device controls the stimulation by moving muscles that are not paralyzed, such as a wrist or neck muscle. the ability of the user to pick up and move objects, as well as perform various activities such as eating, drinking, and writing.

the overall object of this research is to provide restored functional abilities to individuals with cervical-level spinal cord injury through the use of an advanced wireless myoelectrically controlled battery-powered implanted neuroprosthetic system known as the "firsthand" system. this restored function can enable the individual to achieve greater independence in activities of daily living and an improved quality of life. electrical stimulation of paralyzed muscles will be used to generate functional movements. the movements will be controlled using myoelectric signals generated from muscles under the subject's voluntary control. the specific hypotheses of this study are: 1) at least 75% of all subjects will be able to manipulate at least one more object in the grasp-release test when using the advanced neuroprosthesis compared to without the neuroprosthesis. 2) at least 75% of all subjects will demonstrate an increased level of independence in at least one functional activity when using the advanced neuroprosthesis. 3) at least 75% of all subjects will demonstrate an average neuroprosthesis usage of at least three days/week.

Eligibility criteria:
inclusion criteria: * cervical level spinal cord injury; * complete paralysis of fingers and thumbs; * voluntary shoulder motion; * electrically excitable forearm and hand musculature exclusion criteria: * extreme contractures of the joints; * skeletal immaturity; * extensive denervation in the forearm and hand; * poor surgical risk

Keywords: spinal cord injury neuroprosthesis functional electrical stimulation quadriplegia
danhong injection in the treatment of chronic stable angina

Conditions: Chronic Stable Angina

Summary: the purpose of this study is to evaluate the effect of danhong injection on the relief of angina with the use of the seattle angina questionnaire among patients with stable angina patients


Eligibility criteria:
inclusion criteria: * female or male inpatients. * age: 18 - 70 years. * patients with clinical diagnosis of chronic stable angina and must meet one of the following conditions:1）patients who have a history of myocardial infarction and st-t changes;2）stenosis of more than 50% in at least one major epicardial coronary artery shown by coronary angiograph or ct angiography; 3）patients with coronary heart disease were determined by radionuclide angiocardiography. * clinical diagnosis of "xueyu zheng" (blood stasis syndrome) as the scores of chinese medicine symptoms scales of "xueyu zheng" in angina ≥ 15. the chinese medicine symptoms scales of "xueyu zheng" is defined as following (1)chest pain-10, (2)chest distress-10, (3) palpitation-5, (4)purple or dark lip-5, (5) purple or dark tongue-5, (6) unsmooth pulse-5. * patients with moderate angina pectoris (the definition of "moderate angina pectoris " is in accordance with the canadian cardiovascular society (ccs) grading of angina pectoris,which be classified to ii or iii. * patient is willing to participate voluntarily and to sign a written patient informed consent. exclusion criteria: * woman with pregnancy, lactation or positive result of pregnancy test, or woman who is under menstrual period. * woman who disagree with contraception during treatment period * patients with severe complications that would make the condition more complicated assessed by the investigator, including liver or renal dysfunction, severe cardiopulmonary dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, a history of epilepsy or cerebral hemorrhage . * patients who were angina-free during the run-in period without taking any drug. * patients with myocardial infarction or canadian cardiovascular society (ccs) grading of angina pectoris class iv within the preceding 3 months * patients with chest pain caused by other disease (e.g., acute myocardial infarction，severe neurosis，menopausal syndrome，hyperthyroidism). * patients with history of drug-induced bleeding or history of bleeding caused by warfarin. * patients with history of hematopoietic system diseases. * patients who had surgery within the past 4 weeks and have hemorrhagic tendency. * patients who is participating in other trials or has been participated in other trials in recent 3 months. * patients with history of allergy or suspected allergic to the drug. * patients who were suspected addicted into alcohol or drug abuse in the past 2 years. * patients with mental disorder. * patients who were unable to participate in the study as judged by investigator. * patients who were family members or relatives of the research center staffs.

Keywords: chronic stable angina randomized controlled trial traditional chinese medicine
iron deficiency in patients with heart failure and reduced and mildly reduced ejection fraction

Conditions: Iron Deficiency; Heart Failure With Reduced Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction

Summary: a significant percentage of patients with heart failure and reduced ejection fraction (hfref) or mildly reduced ejection fraction (hfmref) have iron deficiency who are symptomatic. this is independently associated with bad quality of life, low functional capacity, lower quality of, life and increased mortality. the prevalence of iron deficiency in hfref and hfmref patients in jordan has not been studied in the past.

the prevalence of chronic heart failure among the industrialized countries is 1-3%, and can exceed 30% in the elderly population. as the population ages, there is an increase in the number of co-morbidities among heart failure patients. these comorbidities are associated with an increase in major adverse cardiac events (mace), cost, and complexity of care. iron deficiency is one of the most common comorbidities occurring in patients with heart failure. its prevalence can be as high as 59%, even if patients are non-anemic\[4\]. iron deficiency in heart failure can lead to an impaired exercise capacity, a decreased quality of life and an increased risk of hospitalizations and mortality regardless of anemia. the relationship between the severity of iron deficiency and the prognosis is a linear one, with increased severity being associated with increased mortality. intravenous iron treatment has been shown to improve the quality of life, with an increased exercise capacity and a reduced risk for hospitalizations. the prevalence of iron deficiency in hfref and hfmref patients in middle eastern population has not been studied. we suspect a higher prevalence compared to western populations especially in women.

Eligibility criteria:
inclusion criteria: * heart failure patients with ejection fraction \<59% (including those with with reduced ejection fraction of ≤40%, or mildly reduced ef (41-49%)) within the last 2 years. * nyha class ii-iv. * able and willing to provide oral informed consent. exclusion criteria: * age\<18 years. * acute coronary syndrome. * known cases of iron overload (e.g. hemochromatosis); known cases of anemia due to other causes. * oral or intravenous iron supplements within the previous 3 months; erythropoietin stimulating agents or blood transfusion within the last 6 months. * active clinically relevant bleeding in the investigator's opinion. * patients with chronic inflammatory conditions (e.g. rheumatoid arthritis; crohn's disease, etc.); active infection; and decompensated liver disease.

Keywords: iron deficiency heart failure heart failure with reduced ejection fraction heart failure with mildly reduced ejection fraction
evaluation of a novel auto segmentation algorithm for normal structure delineation in radiation treatment planning

Conditions: Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm

Summary: this study measures the utility of a novel artificial intelligence (ai) algorithm for performing auto-segmentation of computed tomography (ct) scans for radiation therapy planning.

primary objective: i. to measure the observed utility of an ai algorithm for normal segmentation by recording study subjects' observations of its function. outline: this is an observational study. participants complete surveys about the performance/functionality of the auto-segmentation algorithm on study.

Eligibility criteria:
inclusion criteria: * employment at mayo clinic arizona, florida, or rochester (which includes regional practice sites located at mayo clinic health system locations) as train clinical staff that participate in normal tissue segmentation exclusion criteria: * inability to complete study surveys
to assess the efficacy and safety of oral sildenafil in the treatment of pulmonary arterial hypertension.

Conditions: Pulmonary Arterial Hypertension

Summary: to demonstrate a dose response for 1 mg, 5 mg and 20 mg tid oral sildenafil for the treatment of subjects with pah.


Eligibility criteria:
inclusion criteria: * subjects with pah (i.e. ipah or secondary to connective tissue disease or with surgical repair of asd, vsd, pda, aorto-pulmonary window) whose baseline six minute walk test distance is \>/= 100 m and \</= 450 m. * subjects with a mean pulmonary artery pressure of \>/= 25 mmhg and a pulmonary artery wedge pressure of \</= 15 mmhg at rest via right heart catheterization performed within 12 weeks prior to randomization. exclusion criteria: * subjects whose 6 minute walk distance may be limited by conditions other than pah related dyspnoea or fatigue, e.g. claudication from vascular insufficiency or significant arthritis. * subjects who are currently receiving any forms of chronic treatment for pah such as prostacyclin, pde-5 inhibitors, endothelin-receptor antagonists, nitrates or nitric oxide donors (e.g. arginine supplement, nicorandil) in any form, protease inhibitors such as ritonavir and saquinavir, ketoconazole, itraconazole, and alpha blockers. subjects previously receiving any of these drugs must have stopped use for a period of at least 1 month prior to screening, except in the case of bosentan or prostacyclin (3 months).
prevalence of asthma and rhinitis symptoms among secondary school students in saudi arabia

Conditions: Asthma; Rhinitis

Summary: the purpose of this cross-sectional survey study is to describe the prevalence of asthma and rhinitis symptoms among secondary school students in saudi arabia.

cross sectional survey based on isaac protocol to characterize the symptoms of asthma and rhinitis and measure their frequency and its prevalence among secondary schools students (age 15 to 18 years, boys and girls) in riyadh city, saudi arabia in period from 1st of april 2010 to 31st of may 2010. the isaac protocol stated that the study population should consist of at least 3,000 students aged 15-18 years- in this case, enrolled in at least 40 randomly selected schools. the 15-18 year age group was chosen because it is the age most adolescents go to school regularly, making data collection easier. once requested by the research team, the education authority will provide a list of all secondary schools in riyadh city and the number of students by school and their grades. there are 400 secondary schools for boys and 400 school for girls (total number of boys and girls students 50,000). a two stage stratified random sample of 4000 students will be selected out of secondary schools for boys and girls , their ages range from 16 to 18 years.

Eligibility criteria:
inclusion criteria: * 15:18 year age group exclusion criteria: * younger than 15 years or older than 18 years

Keywords: prevalence of asthma and rhinitis symptoms among secondary school students in saudi arabia